Plants can be engineered to recombinantly produce high-quality proteins such as
therapeutic proteins and vaccines, also known as molecular farming. Molecular farming can …

Current plant-based systems offer multiple advantages for monoclonal antibody (mAb)
development and production beyond the traditional benefits of low cost and high scalability …

Plants offer fast, flexible and easily scalable alternative platforms for the production of
pharmaceutical proteins, but differences between plant and mammalian N‐linked glycans …

Plant molecular farming (PMF) is rapidly gaining traction as a viable alternative to the
currently accepted paradigm of producing biologics. While the platform is potentially …

Production of biologics in plants, or plant molecular pharming, is a promising protein
expression technology that is receiving increasing attention from the pharmaceutical …

Population growth, climate change, and dwindling finite resources are amongst the major
challenges which are facing the planet. Requirements for food, materials, water, and energy …

Paucimannosidic proteins (PMPs) are bioactive glycoproteins carrying truncated α‐or β‐
mannosyl‐terminating asparagine (N)‐linked glycans widely reported across the eukaryotic …

Immunoglobulin M (IgM) is the largest antibody isotype with unique features like extensive
glycosylation and oligomerization. Major hurdles in characterizing its properties are …

N‐glycosylation is critical for recombinant glycoprotein production as it influences the
heterogeneity of products and affects their biological function. In most eukaryotes, the …

Plants are attractive hosts for the production of recombinant glycoproteins for therapeutic
use. Recent advances in glyco‐engineering facilitate the elimination of nonmammalian‐type …